Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $11.75 Consensus Price Target from Brokerages

Regulus Therapeutics Inc. (NASDAQ:RGLS) has earned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $11.75.

RGLS has been the subject of several recent analyst reports. Leerink Partnrs reiterated an “outperform” rating on shares of Regulus Therapeutics in a research note on Monday, March 18th. Canaccord Genuity Group lifted their price target on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Wells Fargo & Company boosted their price objective on Regulus Therapeutics from $2.00 to $3.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 13th. StockNews.com began coverage on shares of Regulus Therapeutics in a report on Tuesday, April 16th. They set a “sell” rating on the stock. Finally, HC Wainwright raised their price target on Regulus Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th.

Regulus Therapeutics Price Performance

Shares of NASDAQ RGLS opened at $1.79 on Wednesday. Regulus Therapeutics has a 1 year low of $1.08 and a 1 year high of $3.79. The stock has a market capitalization of $116.86 million, a P/E ratio of -1.22 and a beta of 1.64. The company has a 50-day moving average price of $2.24 and a 200-day moving average price of $1.92.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.14). As a group, equities research analysts anticipate that Regulus Therapeutics will post -0.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Regulus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in RGLS. NEA Management Company LLC purchased a new stake in Regulus Therapeutics in the first quarter worth approximately $18,627,000. RA Capital Management L.P. bought a new position in Regulus Therapeutics during the 1st quarter worth approximately $18,000,000. Vivo Capital LLC bought a new stake in Regulus Therapeutics during the 1st quarter valued at $14,400,000. FMR LLC boosted its position in Regulus Therapeutics by 32.4% during the 3rd quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock valued at $4,033,000 after buying an additional 716,000 shares during the period. Finally, CVI Holdings LLC bought a new stake in Regulus Therapeutics in the 1st quarter worth $4,050,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.